MedTrace Logo

Pucotenlimab Combined with MRG002 for HER2-positive Cancer of Unknown Primary

NCT06869174 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-03-12

No results posted yet for this study

Summary

This study is a single-arm, open-label, multicenter Phase II clinical trial designed to observe and evaluate the efficacy and safety of Pucotenlimab in combination with MRG002 in patients with HER2-positive (IHC 2+ or 3+) cancer of unknown primary.

Conditions

  • Cancer of Unknown Primary

Interventions

DRUG

Pucotenlimab combined with MRG002

Pucotenlimab 200mg iv d1, Q3W MRG002 2.2mg/kg d1, Q3W

Sponsors & Collaborators

  • Zhiguo Luo, MD, PhD

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-08
Primary Completion
2027-03-08
Completion
2028-08-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06869174 on ClinicalTrials.gov